Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

(2011) W. P. Yong et al.   ANNALS OF ONCOLOGY

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

(2011) B. Lowenberg et al.   BLOOD

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

(2011) Andrew X. Zhu et al.   CANCER

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

(2011) George R. Simon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

(2011) S. Pignata et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

(2011) M. N. Fishman et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

(2011) T. Yau et al.   CLINICAL CANCER RESEARCH

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

(2011) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

(2011) D. S. Hong et al.   CLINICAL CANCER RESEARCH

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

(2011) J. Tabernero et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2011) P. A. Janne et al.   CLINICAL CANCER RESEARCH

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

(2011) G. J. Weiss et al.   CLINICAL CANCER RESEARCH

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

(2011) F. A. L. M. Eskens et al.   CLINICAL CANCER RESEARCH

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

(2011) K. B. Kim et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study

(2011) Li Zhang et al.   CLINICAL THERAPEUTICS

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

(2011) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2011) Eric J. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial

(2011) Christopher G. Azzoli et al.   Journal of Thoracic Oncology

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

(2011) M H Kirschbaum et al.   LEUKEMIA

Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity

(2011) S. Fu et al.   MOLECULAR CANCER THERAPEUTICS

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03

(2011) Fabio M. Iwamoto et al.   NEURO-ONCOLOGY

Phase I/II Study of Hepatic Arterial Infusion Chemotherapy With Gemcitabine in Patients With Unresectable Intrahepatic Cholangiocarcinoma (JIVROSG-0301)

(2010) Yoshitaka Inaba et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

(2010) D. S. Boss et al.   ANNALS OF ONCOLOGY

Phase I trial of SU14813 in patients with advanced solid malignancies

(2010) W. Fiedler et al.   ANNALS OF ONCOLOGY

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

(2010) D. J. Jonker et al.   ANNALS OF ONCOLOGY

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

(2010) Jin Li et al.   BMC CANCER

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

(2010) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients

(2010) Chadi Nabhan et al.   CANCER

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

(2010) Andres Forero-Torres et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

(2010) Yasuhito Fujisaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

(2010) Carlos Castaneda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

(2010) Kyle D. Holen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

(2010) Fumihiko Kanai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma

(2010) Junji Furuse et al.   CANCER SCIENCE

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

(2010) H. A. Burris et al.   CLINICAL CANCER RESEARCH

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

(2010) J. Baselga et al.   CLINICAL CANCER RESEARCH

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

(2010) J. P. Eder et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

(2010) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

(2010) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

Differential Effects of Vitamin K1 on AFP and DCP Levels in Patients with Unresectable HCC and in HCC Cell Lines

(2010) Brian I. Carr et al.   DIGESTIVE DISEASES AND SCIENCES

The unclear zone in phase II clinical trials

(2010) Sabrina Allegro et al.   EUROPEAN JOURNAL OF CANCER

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

(2010) Manfred Johannsen et al.   EUROPEAN JOURNAL OF CANCER

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

(2010) W. Blum et al.   HAEMATOLOGICA

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

(2010) Cheryl Ho et al.   INVESTIGATIONAL NEW DRUGS

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

(2010) William Blum et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia

(2010) Bob Löwenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

(2010) Chrystal U. Louis et al.   JOURNAL OF IMMUNOTHERAPY

A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas

(2010) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

(2010) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

(2010) Thomas S. Lin et al.   LEUKEMIA & LYMPHOMA

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

(2009) O Bratt et al.   BRITISH JOURNAL OF CANCER

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

(2009) Paul Haluska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

(2009) Yelena Y. Janjigian et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab

(2009) Kensei Tobinai et al.   CANCER SCIENCE

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

(2009) H. A. Burris et al.   CLINICAL CANCER RESEARCH

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

(2009) G. Batist et al.   CLINICAL CANCER RESEARCH

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

(2009) R. Plummer et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

(2009) John A. Thompson et al.   Clinical Genitourinary Cancer

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

(2009) Arinobu Tojo et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia

(2009) Hisashi Sakamaki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

(2009) Jan C. Buckner et al.   INVESTIGATIONAL NEW DRUGS

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

(2009) William R. Schelman et al.   INVESTIGATIONAL NEW DRUGS

Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors

(2009) Teresa G. Hayes et al.   INVESTIGATIONAL NEW DRUGS

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

(2009) Kuniaki Shirao et al.   INVESTIGATIONAL NEW DRUGS

Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

(2009) Ferry A.L.M. Eskens et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies

(2009) Chiung-Ing Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

(2009) Luis H. Camacho et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia

(2009) Walter Fiedler et al.   LEUKEMIA RESEARCH

Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma

(2009) Sant P Chawla et al.   MOLECULAR THERAPY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

(2009) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group

(2008) Sven T. Langkjer et al.   ACTA ONCOLOGICA

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

(2008) N M G M Appels et al.   BRITISH JOURNAL OF CANCER

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

(2008) Celestia S. Higano et al.   CANCER

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours

(2008) Samir D. Undevia et al.   EUROPEAN JOURNAL OF CANCER

A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma

(2008) Kimberly B. Higginbotham et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase I Study of Adenovirus p53 Administered by Bronchoalveolar Lavage in Patients With Bronchioloalveolar Cell Lung Carcinoma: ECOG 6597

(2008) Vicki Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

(2008) John A. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens

(2008) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

(2008) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

(2008) Begoña Comin-Anduix et al.   Journal of Translational Medicine

Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma

(2008) Surasak Phuphanich et al.   NEURO-ONCOLOGY